SEC For	rm 4 FORM	Л	UNITE) STA	TES S	ECURITI	IFS	ς ανι) F)	КСНА	NG	F CC	MMI	SSION					
						Washington, D.C. 20549										OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					ed pursuar	IT OF CHANGES IN BENEFICIAL OWNER pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									RSHIP			3235-0287 n 0.5	
1. Name and Address of Reporting Person [*] Jimenez Freddy A.						2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]								ck all applie Directo	cable) r	ng Per	son(s) to Iss 10% Ov	vner	
(Last) C/O CE	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 06/15/2023									below)	(give title	RAL	Other (s below) COUNSE		
53 FRONTAGE ROAD, SUITE 220					4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) HAMPTON NJ 08827													X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D.					Execution Date		Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)					es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	t	(A) or (D)	Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			(1130. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Conversion or Exercise Price of Derivative 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date if any (Month/Day/Year)			Date,	1. Fransactior Code (Instr. 3)	ransaction of ode (Instr. Derivative			6. Date Exercisable and Expiration Date Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security		8. Price of Derivative Security (Instr. 5)	erivative ecurity Securities		10. Ownership Form: Direct (D) or Indirect	Beneficial Ownershi	

Explanation of Responses:

\$36.87

Security

Incentive Stock Option

(right to buy)⁽¹⁾

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

06/15/2023⁽¹⁾

2. 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Code v (A)

A

Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

74,000

Date

(D)

Exercisable

06/15/2024⁽²⁾

/s/ Sam Martin, attorney-in-fact 06/20/2023 for Freddy A. Jimenez

(Instr. 4)

Following Reported Transaction(s)

74,000

\$<mark>0</mark>

(Instr. 3 and 4)

Title

Commo

Stock

Expiration

06/15/2033

Date

Amount or Number

of Shares

74,000

(I) (Instr. 4)

D

Beneficial Ownership (Instr. 4)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.